• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Correction to: Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.

出版信息

Br J Dermatol. 2024 Nov 18;191(6):e26-e27. doi: 10.1093/bjd/ljae338.

DOI:10.1093/bjd/ljae338
PMID:39226086
Abstract
摘要

相似文献

1
Correction to: Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.对《奈莫利珠单抗与外用糖皮质激素治疗结节性痒疹的疗效和安全性：≥13岁患者的随机双盲安慰剂对照II/III期临床研究结果》的勘误
Br J Dermatol. 2024 Nov 18;191(6):e26-e27. doi: 10.1093/bjd/ljae338.
2
Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.尼莫利珠单抗联合外用皮质类固醇治疗结节性痒疹的疗效和安全性：一项在年龄≥13 岁患者中进行的随机、双盲、安慰剂对照的 II/III 期临床研究结果。
Br J Dermatol. 2024 Jul 16;191(2):200-208. doi: 10.1093/bjd/ljae131.
3
Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged ≥ 13 years: efficacy and safety data from a phase II/III study.≥13岁结节性痒疹患者长期（68周）使用奈莫利单抗和外用皮质类固醇：一项II/III期研究的疗效和安全性数据
Br J Dermatol. 2025 Jun 20;193(1):56-65. doi: 10.1093/bjd/ljaf045.
4
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.尼莫利珠单抗治疗中重度结节性痒疹的试验。
N Engl J Med. 2020 Feb 20;382(8):706-716. doi: 10.1056/NEJMoa1908316.
5
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.奈莫利单抗治疗中度至重度结节性痒疹患者的疗效和安全性：OLYMPIA 1随机临床3期试验
JAMA Dermatol. 2025 Feb 1;161(2):147-156. doi: 10.1001/jamadermatol.2024.4796.
6
Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies.在特应性皮炎和结节性痒疹3期研究中，奈莫利珠单抗可使瘙痒迅速改善。
J Eur Acad Dermatol Venereol. 2025 Dec 16. doi: 10.1111/jdv.70250.
7
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.尼莫利珠单抗治疗结节性痒疹患者的 3 期临床试验。
N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333.
8
Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study.尼莫利珠单抗治疗 6-12 岁中重度瘙痒特应性皮炎患儿的疗效和安全性：一项 III 期、随机、双盲、安慰剂对照、多中心研究的结果。
Br J Dermatol. 2023 Dec 20;190(1):20-28. doi: 10.1093/bjd/ljad268.
9
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.奈莫利珠单抗治疗结节性痒疹长达100周：OLYMPIA LTE中期分析。
J Eur Acad Dermatol Venereol. 2025 Dec 17. doi: 10.1111/jdv.70266.
10
Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.尼莫利珠单抗治疗结节性痒疹的疗效：对瘙痒和睡眠障碍的起效时间。
J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1820-1825. doi: 10.1111/jdv.18377. Epub 2022 Jul 4.

引用本文的文献

1
European S2k Guideline on Chronic Pruritus.欧洲慢性瘙痒症S2k指南。
Acta Derm Venereol. 2025 Aug 22;105:adv44220. doi: 10.2340/actadv.v105.44220.